Cancers, Vol. 12, Pages 2212: Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei —A Novel Treatment Approach

Cancers, Vol. 12, Pages 2212: Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei—A Novel Treatment Approach Cancers doi: 10.3390/cancers12082212 Authors: Aruna Prabhu Andreas Brandl Satoshi Wakama Shouzou Sako Haruaki Ishibashi Akiyoshi Mizumoto Nobuyuki Takao Kousuke Noguchi Shunsuke Motoi Masumi Ichinose Yang Liu Yutaka Yonemura Neoadjuvant intravenous chemotherapy in patients with pseudomyxoma peritonei (PMP) has not shown convincing results. The effectiveness of neoadjuvant intraperitoneal (IP) chemotherapy has never been reported. This prospective, non-randomized phase II study included patients with PMP treated between May 2017 and December 2018, who were not considered suitable for primary cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The majority of patients were treated with laparoscopic HIPEC (oxaliplatin 200 mg/m2, 60 min, 43 °C). IP chemotherapy was started 2 weeks after docetaxel 40 mg/m2 + cisplatin 40 mg/m2, accompanied by oral S1 (tegafur, gimeracil, and oteracil) (50 mg/m2) for 14 days, followed by one week rest. Clinical parameters and complications were recorded. In total, 22/27 patients qualified for CRS and HIPEC after neoadjuvant treatment. A complete cytoreduction (Completeness of cytoreduction Score 0/1) could be achieved in 54.5%. The postoperative morbidity rate was 13.6% and mortality was rate 4.5%. In total, 20/22 patients had major pathol...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research